IMPACT OF RED CELL EXCHANGE TRANSFUSION ON INFLAMMATORY MARKERS IN SICKLE CELL DISEASE
Main Article Content
Keywords
Red Cell Exchange Transfusion, Sickle Cell Disease, Inflammatory Markers, cerebrovascular disease
Abstract
Background: Red Blood Cell Exchange (RBCX) is a common treatment for pediatric sickle cell disease (SCD), particularly in cases complicated by cerebrovascular disease. Since inflammation plays a crucial role in SCD and elevated pro-inflammatory cytokines are observed in these patients, this study hypothesized that RBCX might lower these cytokines and aimed to assess the impact of this technique on these markers.
Methods: This prospective and observational study included pediatric SCD patients (HbSS genotype) enrolled in a chronic RBCX program at a Portuguese Hospital from October 2022 to May 2024. Patients with acute exacerbations were excluded. Blood samples were collected before and after RBCX to assess hematological parameters and inflammatory cytokines. Data were analyzed using SPSSv25Ⓡ (Significance level set at p < 0.05); Informed consents were obtained.
Results: Thirty-one children (median age 10 years) were studied. Fourteen patients were new to RBCX, while 17 were already in a chronic RBCX program. RBCX mainly aimed to prevent cerebrovascular disease (81%). A total of 286 RBCXs were analyzed, showing no major adverse events or disease-related hospitalizations. Hemoglobin levels increased by 1.5g/dL, HbS decreased by 69%, and leukocytes decreased by 20%. IL-1, ferritin and procalcitonin showed high levels before RBCX. IL-1 levels dropped significantly post-RBCX (p<0.001), while other markers like C-Reactive Protein, IL-6, and TNF-α showed no significant changes.
Conclusions: RBCX safely reduces HbS, leukocytes, and IL-1 levels, suggesting a modulatory effect on inflammation in SCD patients. Further research is needed to explore cytokine mechanisms in SCD.
Downloads
Abstract 351
PDF Downloads 149
HTML Downloads 29
References
2. Zahran AM, Nafady A, Saad K, Hetta HF, Abdallah AM, Abdel-Aziz SM, Embaby MM, Abo Elgheet AM, Darwish SF, Abo-Elela MGM, Elhoufey A, Elsayh KI. Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029619895111. https://doi.org/10.1177/1076029619895111. PMID: 31942811; PMCID: PMC7098201.
3. Keikhaei B, Mohseni AR, Norouzirad R, Alinejadi M, Ghanbari S, Shiravi F, Solgi G. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw. 2013 Mar;24(1):45-52. https://doi.org/10.1684/ecn.2013.0328. PMID: 23608554.
4. Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol. 2004 Dec;77(4):323-8. doi: 10.1002/ajh.20196. PMID: 15551290.)
5. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:48-53. https://doi.org/10.1182/asheducation-2006.1.48. PMID: 17124039.
6. Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):625-631. https://doi.org/10.1182/asheducation-2016.1.625. PMID: 27913538; PMCID: PMC6142434.
7. Chou, S. T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., Stowell, S. R., Thein, S. L., Westhoff, C. M., Wong, T. E., & Akl, E. A. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood advances, 4(2), 327–355. https://doi.org/10.1182/bloodadvances.2019001143
8. Sarray S, Saleh LR, Lisa Saldanha F, Al-Habboubi HH, Mahdi N, Almawi WY. Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition. Cytokine. 2015 Mar;72(1):43-7. https://doi.org/10.1016/j.cyto.2014.11.030. Epub 2015 Jan 5. PMID: 25569375.
9. Pedrosa AM, Leal LKAM, Lemes RPG. Effects of hydroxyurea on cytotoxicity, inflammation and oxidative stress markers in neutrophils of patients with sickle cell anemia: dose-effect relationship. Hematol Transfus Cell Ther. 2021 Oct-Dec;43(4):468-475. https://doi.org/10.1016/j.htct.2020.07.011. Epub 2020 Sep 30. PMID: 33051133; PMCID: PMC8573033.
10. Liem RI, O'Gorman MR, Brown DL. Effect of red cell exchange transfusion on plasma levels of inflammatory mediators in sickle cell patients with acute chest syndrome. Am J Hematol. 2004 May;76(1):19-25. https://doi.org/10.1002/ajh.20054. PMID: 15114592.
11. Venugopal J, Wang J, Mawri J, Guo C, Eitzman D. Interleukin-1 receptor inhibition reduces stroke size in a murine model of sickle cell disease. Haematologica. 2021 Sep 1;106(9):2469-2477. https://doi.org/10.3324/haematol.2020.252395. PMID: 32817286; PMCID: PMC8409048.
12. Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018;68(2-3):263-299. https://doi.org/10.3233/CH-189012. PMID: 29614637; PMCID: PMC6314308.
13. Tanhehco YC, Shi PA, Schwartz J. Transfusion therapy in sickle cell disease. Ann Blood. 2022;7:9. https://doi.org/10.21037/aob-21-67.
14. Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Evans C, Vichinsky EP. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher. 1999;14(3):122-125. PMID: 10589704.
15. Hilliard LM, Williams BF, Lounsbury AE, Howard TH. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol. 1998;59:28-35. PMID: 9709632.
16. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:48-53. https://doi.org/10.1182/asheducation-2006.1.48. PMID: 17124039.
17. Nader E, Romana M, Connes P. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease. Front Immunol. 2020 Mar 13;11:454. https://doi.org/10.3389/fimmu.2020.00454. PMID: 32231672; PMCID: PMC7082402.
18. Siransy LK, Dasse RS, Adou H, Kouacou P, Kouamenan S, Sekongo Y, Yeboah R, Memel C, Assi-Sahoin A, Moussa SY, Oura D, Seri J. Are IL-1 family cytokines important in management of sickle cell disease in Sub-Saharan Africa patients? Front Immunol. 2023 Mar 9;14:954054. doi: 10.3389/fimmu.2023.954054. PMID: 36969226; PMCID: PMC10034065.
19. Kazmi, S., Salehi-Pourmehr, H., Sadigh-Eteghad, S., & Farhoudi, M. (2024). The efficacy and safety of interleukin-1 receptor antagonist in stroke patients: A systematic review. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 120, 120–128. https://doi.org/10.1016/j.jocn.2024.01.009
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.